熱門資訊> 正文

Checkpoint Therapeutics GAAP每股收益为-1.42美元

2025-03-28 20:32

Checkpoint Therapeutics, Inc.(CKPT) 0

Checkpoint Therapeutics press release (NASDAQ:CKPT): FY GAAP EPS of -$1.42.
As of December 31, 2024, Checkpoint’s cash and cash equivalents totaled $6.6 million, compared to $4.9 million at December 31, 2023, an increase of $1.7 million. Subsequent to the end of the fiscal year, Checkpoint received approximately $38.1 million in cash proceeds through the exercise of existing warrants.

More on Checkpoint Therapeutics

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics: Pivoting From Approval To Gutsy Next Shot On Goal
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
Seeking Alpha’s Quant Rating on Checkpoint Therapeutics
Historical earnings data for Checkpoint Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。